Lineage Cell Therapeutics

Lineage Cell Therapeutics Current Assets

The Current Assets of Lineage Cell Therapeutics (LCTX) as of Oct 31, 2026 is 58.49 M USD. In the previous year, Current Assets was 51.00 M USD — a change of 14.69% (higher).

Current Assets

58.49 MUSD

YoY

14.69%

Last updated:

Current Assets of Lineage Cell Therapeutics is 2025 58.49 M USD. Current Assets of Lineage Cell Therapeutics was 2024 51.00 M USD. It decreases by 14.69% higher compared to the previous year.

The Lineage Cell Therapeutics Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
36.34 M USD
Jan 1, 2019
56.68 M USD
Jan 1, 2020
44.00 M USD
Jan 1, 2021
111.21 M USD
Jan 1, 2022
60.00 M USD
Jan 1, 2023
38.44 M USD
Jan 1, 2024
51.00 M USD
Jan 1, 2025
58.49 M USD
The Lineage Cell Therapeutics Current Assets history
YEARCurrent AssetsYoY
58.49 MUSD+14.69%
51.00 MUSD+32.66%
38.44 MUSD-35.93%
60.00 MUSD-46.04%
111.21 MUSD+152.78%
44.00 MUSD-22.38%
56.68 MUSD+55.97%
36.34 MUSD-14.65%
42.58 MUSD+65.72%
25.69 MUSD-46.21%
47.76 MUSD+45.78%
32.76 MUSD+312.90%
7.93 MUSD-8.58%
8.68 MUSD-66.56%
25.96 MUSD-28.44%
36.27 MUSD+190.08%
12.50 MUSD+5,985.86%
205,469.00USD-24.95%
273,791.00USD-55.75%
618,692.00USD-67.97%
1.93 MUSD+19.59%
1.62 MUSD+60.39%
1.01 MUSD-27.14%
1.38 MUSD-21.57%
1.76 MUSD+22.29%
1.44 MUSD-73.32%
5.40 MUSD+100.00%
2.70 MUSD-37.21%
4.30 MUSD-47.56%
8.20 MUSD+192.86%
2.80 MUSD-20.00%
3.50 MUSD-39.66%
5.80 MUSD+65.71%
3.50 MUSD-27.08%
4.80 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lineage Cell Therapeutics Stock analysis

What does Lineage Cell Therapeutics do? Lineage Cell Therapeutics Inc. is a biopharmaceutical company that focuses on the development and commercialization of cell therapies for various diseases. Originally established in 1990 as VisiGenics Inc., specializing in proteomic and genetic analysis, the company later changed its name to Lineage Cell Therapeutics Inc. to reflect its focus on the research and development of stem cell therapies. Lineage Cell Therapeutics develops and markets cell therapy products based on its own patents and discoveries, including therapies for eye, neurodegenerative, and cancer diseases. The company's proprietary technology platform gives it a crucial position in the field of cell therapy. Additionally, Lineage Cell Therapeutics collaborates with academic institutions and other biopharmaceutical companies to expedite the process of commercializing cell therapies. The company offers a wide range of cell therapies for various injuries and diseases, with key applications including: - OPC1: A cell-based therapy for spinal cord injuries caused by damage to the spinal cord. This therapy is being developed on the astrocyte differentiation treatment platform derived from embryonic stem cells (ES cells). - OpRegen: A cell-based regenerative product for dry age-related macular degeneration (tAMD). This therapy is based on the retinal pigment epithelium cell differentiation treatment platform derived from human embryonic stem cells. - VAC: An immunotherapy for cancer treatment. This treatment involves dendritic cells isolated from the patient's blood and genetically modified to present cancer-specific antigens. The goal is to stimulate the patient's immune system to trigger a specific immune response against cancer. Lineage Cell Therapeutics also pursues a strong expansion strategy. In 2020, it acquired a majority stake in AgeX Therapeutics, a biotechnology company focused on developing innovations in the field of stem cells. This acquisition strengthened the company's capacity for innovation and increased its ability to capitalize on future growth opportunities through partnerships, licensing, and product launches. Overall, Lineage Cell Therapeutics has become a significant player in the field of cell therapy, thanks to the use of cutting-edge technology and years of experience in the life science industry. One of the company's main goals is to develop and manufacture groundbreaking cell therapies to ultimately improve the lives of patients worldwide. Lineage Cell Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lineage Cell Therapeutics stock

Current Assets of Lineage Cell Therapeutics is 58.49 M USD in 2025.

Current Assets of Lineage Cell Therapeutics changed from 51.00 M USD to 58.49 M USD, representing a 14.69% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Lineage Cell Therapeutics since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Lineage Cell Therapeutics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Lineage Cell Therapeutics

All Key Metrics — Lineage Cell Therapeutics